Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?

Citation
R. Goshen et al., Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?, GYNECOL ONC, 79(3), 2000, pp. 477-481
Citations number
28
Categorie Soggetti
Reproductive Medicine
Journal title
GYNECOLOGIC ONCOLOGY
ISSN journal
00908258 → ACNP
Volume
79
Issue
3
Year of publication
2000
Pages
477 - 481
Database
ISI
SICI code
0090-8258(200012)79:3<477:IUPSAA>2.0.ZU;2-9
Abstract
Background, Uterine papillary serous carcinoma (UPSC) shares common patholo gic, genetic, and clinical features with other serous cancers of mullerian origin. The most common histologic type of ovarian tumor associated with BR CA mutations is papillary serous. Because of these histologic similarities, we postulated that, in some cases, UPSC may be a manifestation of a field defect in BRCA1 carriers, which also includes ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma, Methods, Fifty-six living patients with UPSC were contacted through their t reating physicians and agreed to a family history interview and to provide a blood specimen for BRCA testing. The protein truncation test was used to detect mutations in exons 10 and 11 of BRCA1 and in exon 11 of BRCA2, The p resence of four common mutations was assessed by PCR-based specific assays. Results. A high proportion of patients had a past history of breast cancer (11%) or a first-degree relative with breast cancer (29%). Four patients we re from families with site-specific hereditary breast cancer, However, ther e was no clear example of the hereditary breast-ovarian cancer syndrome, an d none of the 56 patients was found to carry a BRCA1 or BRCA2 mutation. Conclusions. BRCA mutations do not appear to predispose to UPSC and this ty pe of cancer does not appear to be a manifestation of the classical heredit ary breast-ovarian cancer syndrome. The observed association between UPSC a nd breast cancer may be due to the presence of mutations in other cancer pr edisposing genes. (C) 2000 Academic Press.